113 related articles for article (PubMed ID: 17438058)
21. Pentosan polysulfate as a prophylactic and therapeutic agent against prion disease.
Dealler S; Rainov NG
IDrugs; 2003 May; 6(5):470-8. PubMed ID: 12789602
[TBL] [Abstract][Full Text] [Related]
22. Immunization with recombinant bovine but not mouse prion protein delays the onset of disease in mice inoculated with a mouse-adapted prion.
Ishibashi D; Yamanaka H; Yamaguchi N; Yoshikawa D; Nakamura R; Okimura N; Yamaguchi Y; Shigematsu K; Katamine S; Sakaguchi S
Vaccine; 2007 Jan; 25(6):985-92. PubMed ID: 17055125
[TBL] [Abstract][Full Text] [Related]
23. Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner.
Kawasaki Y; Kawagoe K; Chen CJ; Teruya K; Sakasegawa Y; Doh-ura K
J Virol; 2007 Dec; 81(23):12889-98. PubMed ID: 17881452
[TBL] [Abstract][Full Text] [Related]
24. Immunisation strategies against prion diseases: prime-boost immunisation with a PrP DNA vaccine containing foreign helper T-cell epitopes does not prevent mouse scrapie.
Nitschke C; Flechsig E; van den Brandt J; Lindner N; Lührs T; Dittmer U; Klein MA
Vet Microbiol; 2007 Aug; 123(4):367-76. PubMed ID: 17499458
[TBL] [Abstract][Full Text] [Related]
25. Transgenetic investigations of prion diseases of humans and animals.
Prusiner SB
Philos Trans R Soc Lond B Biol Sci; 1993 Feb; 339(1288):239-54. PubMed ID: 8097053
[TBL] [Abstract][Full Text] [Related]
26. Prion protein self-interactions: a gateway to novel therapeutic strategies?
Rigter A; Langeveld JP; van Zijderveld FG; Bossers A
Vaccine; 2010 Nov; 28(49):7810-23. PubMed ID: 20932496
[TBL] [Abstract][Full Text] [Related]
27. Genetics of prion diseases and prion diversity in mice.
Carlson GA; DeArmond SJ; Torchia M; Westaway D; Prusiner SB
Philos Trans R Soc Lond B Biol Sci; 1994 Mar; 343(1306):363-9. PubMed ID: 7913753
[TBL] [Abstract][Full Text] [Related]
28. Preparation of soluble infectious samples from scrapie-infected brain: a new tool to study the clearance of transmissible spongiform encephalopathy agents during plasma fractionation.
Berardi VA; Cardone F; Valanzano A; Lu M; Pocchiari M
Transfusion; 2006 Apr; 46(4):652-8. PubMed ID: 16584444
[TBL] [Abstract][Full Text] [Related]
29. Epitope scanning reveals gain and loss of strain specific antibody binding epitopes associated with the conversion of normal cellular prion to scrapie prion.
Pan T; Li R; Kang SC; Wong BS; Wisniewski T; Sy MS
J Neurochem; 2004 Sep; 90(5):1205-17. PubMed ID: 15312175
[TBL] [Abstract][Full Text] [Related]
30. Microglial cell line established from prion protein-overexpressing mice is susceptible to various murine prion strains.
Iwamaru Y; Takenouchi T; Ogihara K; Hoshino M; Takata M; Imamura M; Tagawa Y; Hayashi-Kato H; Ushiki-Kaku Y; Shimizu Y; Okada H; Shinagawa M; Kitani H; Yokoyama T
J Virol; 2007 Feb; 81(3):1524-7. PubMed ID: 17121794
[TBL] [Abstract][Full Text] [Related]
31. A novel copper-hydrogen peroxide formulation for prion decontamination.
Solassol J; Pastore M; Crozet C; Perrier V; Lehmann S
J Infect Dis; 2006 Sep; 194(6):865-9. PubMed ID: 16941355
[TBL] [Abstract][Full Text] [Related]
32. Immunoaffinity purification and neutralization of scrapie prions.
Gabizon R; McKinley MP; Groth D; Westaway D; DeArmond SJ; Carlson GA; Prusiner SB
Prog Clin Biol Res; 1989; 317():583-600. PubMed ID: 2574871
[TBL] [Abstract][Full Text] [Related]
33. Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice.
Pfeifer A; Eigenbrod S; Al-Khadra S; Hofmann A; Mitteregger G; Moser M; Bertsch U; Kretzschmar H
J Clin Invest; 2006 Dec; 116(12):3204-10. PubMed ID: 17143329
[TBL] [Abstract][Full Text] [Related]
34. Oral Fucoidan Attenuates Lung Pathology and Clinical Signs in a Severe Influenza a Mouse Model.
Richards C; Williams NA; Fitton JH; Stringer DN; Karpiniec SS; Park AY
Mar Drugs; 2020 May; 18(5):. PubMed ID: 32397317
[TBL] [Abstract][Full Text] [Related]
35. Upgrading the antioxidant properties of fucoidan and alginate from Cystoseira trinodis by fungal fermentation or enzymatic pretreatment of the seaweed biomass.
Hifney AF; Fawzy MA; Abdel-Gawad KM; Gomaa M
Food Chem; 2018 Dec; 269():387-395. PubMed ID: 30100450
[TBL] [Abstract][Full Text] [Related]
36. Amyloidophilic compounds for prion diseases.
Teruya K; Kawagoe K; Kimura T; Chen CJ; Sakasegawa Y; Doh-ura K
Infect Disord Drug Targets; 2009 Feb; 9(1):15-22. PubMed ID: 19200011
[TBL] [Abstract][Full Text] [Related]
37. Can prions hitch-hike across the species barrier?
Hayward P
Lancet Neurol; 2005 Feb; 4(2):81. PubMed ID: 15709222
[No Abstract] [Full Text] [Related]
38. Absorption Study of Mozuku Fucoidan in Japanese Volunteers.
Kadena K; Tomori M; Iha M; Nagamine T
Mar Drugs; 2018 Jul; 16(8):. PubMed ID: 30061499
[TBL] [Abstract][Full Text] [Related]
39. Detection of Fucoidan in Urine after Oral Intake of Traditional Japanese Seaweed, Okinawa mozuku (Cladosiphon okamuranus Tokida).
Tokita Y; Hirayama M; Nakajima K; Tamaki K; Iha M; Nagamine T
J Nutr Sci Vitaminol (Tokyo); 2017; 63(6):419-421. PubMed ID: 29332904
[TBL] [Abstract][Full Text] [Related]
40. Comparative Study of Fucoidan from
Tan J; Wang J; Geng L; Yue Y; Wu N; Zhang Q
Mar Drugs; 2020 Feb; 18(3):. PubMed ID: 32120786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
